Over 100 Total Lots Up For Auction at One Location - CA 12/04

Accuray CyberKnife robotic radiotherapy platform superior to linear accelerators for bladder side effects of prostate cancer

Press releases may be edited for formatting or style | September 14, 2021 Rad Oncology

When the prostate moves, the CyberKnife® System, the first and only robotic radiotherapy delivery system, detects this movement and uses artificial intelligence (AI) to synchronize the treatment delivery beam to the prostate's new position in real-time throughout the entire treatment session. This synchronization occurs automatically, making it unnecessary to significantly expand treatment margins or reposition the patient – approaches used by conventional linear accelerators. The CyberKnife® robot, guided by the Accuray proprietary AI-driven Synchrony® technology, can deliver radiation from virtually any angle – facilitating the delivery of sub-millimeter accuracy throughout the procedure even as the prostate moves unpredictably.

"CyberKnife prostate SBRT is supported by the most extensive clinical experience in the industry. The PACE trial adds to the available data and provides further compelling evidence of the difference the technology can make in a patient's life and the value it can bring to a hospital's prostate cancer treatment program," said Jean-Philippe Pignol, M.D., Ph.D., chief medical & technology officer at Accuray.

About the PACE-B Trial
The PACE trial data provides level 1 clinical evidence – the strongest level of evidence on which to guide practice changes. PACE-B is a prospective, randomized trial conducted in 37 centers in the UK, Canada and Ireland, comparing five-fraction stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer. The PACE-B trial is funded by Accuray, sponsored by The Royal Marsden and coordinated by the ICR-CTSU at The Institute of Cancer Research, London. Of the 874 patients enrolled, data up to two years on 848 patients treated with radiotherapy were analyzed; 415 receiving SBRT and 433 CFMHRT. Forty-one percent of men treated with SBRT in the study received treatment using the CyberKnife platform.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.

SOURCE Accuray Incorporated

Back to HCB News

You Must Be Logged In To Post A Comment